Skip to main content

RSV Vaccines News

News
08/22/2023
According to recent research, including recombinant RSV prefusion conformation-stabilized fusion protein in the vaccine improved the overall effectiveness in generating immune reactions in older patients.
According to recent research, including recombinant RSV prefusion conformation-stabilized fusion protein in the vaccine improved the overall effectiveness in generating immune reactions in older patients.
According to recent research,...
08/22/2023
First Report Managed Care
News
08/10/2023
Recent clinical trial findings indicate that the RSVpreF vaccine demonstrated efficacy in preventing RSV-associated respiratory illnesses in older adults with no significant safety concerns.
Recent clinical trial findings indicate that the RSVpreF vaccine demonstrated efficacy in preventing RSV-associated respiratory illnesses in older adults with no significant safety concerns.
Recent clinical trial findings...
08/10/2023
First Report Managed Care
News
07/24/2023
"Our analysis provides contemporary estimates of the population-level RSV disease burden and insights into the economic value drivers for RSV vaccination," said researchers. 
"Our analysis provides contemporary estimates of the population-level RSV disease burden and insights into the economic value drivers for RSV vaccination," said researchers. 
"Our analysis provides...
07/24/2023
First Report Managed Care
News
07/19/2023
Researchers tested RSV mRNA vaccine V171 through a relative potency assay to assess its ability to induce humoral and cellular immunity responses. 
Researchers tested RSV mRNA vaccine V171 through a relative potency assay to assess its ability to induce humoral and cellular immunity responses. 
Researchers tested RSV mRNA...
07/19/2023
First Report Managed Care
News
06/27/2023
The findings of a phase 2a trial show the MVA-BN-RSV vaccine reduced respiratory syncytial virus load, symptoms, and infections while eliciting immune responses.
The findings of a phase 2a trial show the MVA-BN-RSV vaccine reduced respiratory syncytial virus load, symptoms, and infections while eliciting immune responses.
The findings of a phase 2a trial...
06/27/2023
First Report Managed Care
News
06/26/2023
Human respiratory syncytial virus (RSV) strains cluster into distinct groups based on T cell epitope profiles, indicating divergent immunogenic profiles and highlighting the need for different vaccine strategies for RSV-A and RSV-B groups.
Human respiratory syncytial virus (RSV) strains cluster into distinct groups based on T cell epitope profiles, indicating divergent immunogenic profiles and highlighting the need for different vaccine strategies for RSV-A and RSV-B groups.
Human respiratory syncytial...
06/26/2023
First Report Managed Care
News
04/26/2023
Researchers evaluated the Ad26.RSV.pre-F vaccine's efficacy in a proof-of-concept study involving several thousand older adults.
Researchers evaluated the Ad26.RSV.pre-F vaccine's efficacy in a proof-of-concept study involving several thousand older adults.
Researchers evaluated the...
04/26/2023
First Report Managed Care
News
04/21/2023
“It is likely that multiple immunization strategies with complementary value, unique advantages, and use-case scenarios will shape the RSV prevention landscape," researchers said.
“It is likely that multiple immunization strategies with complementary value, unique advantages, and use-case scenarios will shape the RSV prevention landscape," researchers said.
“It is likely that multiple...
04/21/2023
Pharmacy Learning Network
News
04/20/2023
Researchers said outcomes will likely improve with future vaccine modifications and alterations to the study population.
Researchers said outcomes will likely improve with future vaccine modifications and alterations to the study population.
Researchers said outcomes will...
04/20/2023
First Report Managed Care
News
03/31/2023
Data from an ongoing phase 3 trial suggest a vaccine for respiratory syncytial virus is efficacious for preventing infection and severe disease in older adults.
Data from an ongoing phase 3 trial suggest a vaccine for respiratory syncytial virus is efficacious for preventing infection and severe disease in older adults.
Data from an ongoing phase 3...
03/31/2023
First Report Managed Care